Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ACAD with free AI briefings, catalyst countdowns, and dilution alerts.

ACAD · ACADIA Pharmaceuticals Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$976.4M Cash on Hand
CF+ Cash Runway
Follow ACAD by email Get an email when ACAD reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ACAD, unsubscribe in one click. Privacy

📣 What ACAD Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Pimavanserin Tartrate
FDA approved Apr 2016 · Nuplazid
Parkinson's Disease Psychosis Phase 3 · NCT01174004 Completed
Trofinetide
FDA approved Mar 2023 · Daybue
Rett Syndrome Phase 3 · NCT04776746 Terminated
ACP-204 Lewy Body Dementia Psychosis Phase 3 · NCT07095465 Recruiting
Carbetocin Hyperphagia in Prader-Willi Syndrome Phase 3 · NCT06173531 Completed
ACP-044 Dose A Osteoarthritis Pain Phase 2 · NCT05008835 Terminated
ACP-044 Dose B Osteoarthritis Pain Phase 2 · NCT05008835 Terminated
ACP-104 Schizophrenia Phase 2 · NCT00490516 Completed
ACP-211 Major Depressive Disorder (MDD) Phase 2 · NCT07284667 Recruiting
Active drug: pimavanserin 17mg (2 strength… Parkinson Disease Phase 2 · NCT03947216 Completed
Pimavanserin 34 milligrams (MG) [Nuplazid] Schizophrenia Phase 2 · NCT03994965 Withdrawn

Also used in these trials (approved or third-party drugs, not ACAD's own candidates): Pimavanserin, Quetiapine.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ACAD holds $976.4M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ACAD files for a raise →

👥 Who Owns ACAD

Insiders 23% Institutions (471 holders) 77% Public and other holders 0%
HolderTypeShares% of sharesAs of
Julian C. Baker Institution (13G, 5%+) 43,294,373 25.05% 2026-02-24
BAKER BROS. ADVISORS LP
Director, 10% owner · +32,008 options
Insider 39,487,463 22.85% 2026-05-29
Vanguard Portfolio Management Institution (13G, 5%+) 8,781,007 5.08% 2026-03-31
Mark C. Schneyer
EVP, CHIEF FINANCIAL OFFICER · +157,929 options
Insider 71,322 0.04% 2026-10-15
Daniel B Soland
Director · +21,900 options
Insider 44,041 0.03% 2025-05-29
Edmund Harrigan
Director · +39,108 options
Insider 43,148 0.02% 2026-05-29
Elizabeth A. Garofalo
Director · +39,108 options
Insider 33,489 0.02% 2026-05-29
Adora Ndu
Director · +39,108 options
Insider 32,908 0.02% 2026-05-29
Laura Brege
Director · +25,315 options
Insider 23,202 0.01% 2026-05-29
Elizabeth H.Z. Thompson
EVP, Head of Research & Dev · +133,846 options
Insider 18,994 0.01% 2026-07-29
Adams Catherine Owen
Chief Executive Officer, Director · +333,535 options
Insider 14,803 0.01% 2026-03-24
James Kihara
PRINCIPAL ACCOUNTING OFFICER · +24,362 options
Insider 13,088 0.01% 2026-06-26

Share count 172,828,972 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full ACAD picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ACAD and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.